APOE and Alzheimer disease: The strength of the diagnoses in the ESTHER study has been supported by previous work, in which the APOE ε4–AD polygenic risk score distribution among dementia diagnoses closely mirror that in the established literature.17 In addition, the limited number of dementia-related biomarker measurements and relatively small number of participants with an eGFRcr-cys less than 30 mL/min/1.73 m2 may limit the interpretation of the results.